• Intraarticular Resiniferatoxin for Osteoarthritic Pain Relie

  2026-06-05

  The reference study evaluates intraarticular resiniferatoxin (RTX), an ultra-potent TRPV1 agonist, as a novel intervention for osteoarthritis (OA) pain. By targeting and chemically inactivating TRPV1-positive sensory nerve endings, RTX offers long-lasting analgesia with a distinct mechanism compared to conventional treatments, highlighting its translational promise.

• PQQ Attenuates Age-Related Osteoarthritis via Nrf2–IGF1R Axi

  2026-06-05

  This study demonstrates that long-term dietary pyrroloquinoline quinone (PQQ) protects against age-related osteoarthritis in mice by activating the Nrf2-mediated antioxidant response and upregulating IGF1R signaling. The findings provide mechanistic insight into redox regulation in cartilage homeostasis and suggest a potential disease-modifying strategy for osteoarthritis.

• Applied Use-Cases of Toremifene Citrate in Breast Cancer Res

  2026-06-04

  Toremifene Citrate is a cornerstone oral selective estrogen receptor modulator for advanced breast cancer and hormone receptor pathway research. This article delivers actionable workflows, troubleshooting strategies, and comparative insights that maximize reproducibility and assay performance.

• TSPAN18 Stabilizes STIM1 to Drive Prostate Cancer Bone Metas

  2026-06-04

  Zhou et al. (2023) reveal that TSPAN18 promotes prostate cancer bone metastasis by protecting STIM1 from TRIM32-mediated ubiquitination, thereby enhancing store-operated calcium entry (SOCE) and activating the calcium signaling pathway. These findings identify TSPAN18 as a key modulator of metastatic progression and a potential therapeutic target for advanced prostate cancer.

• Targeting DDX3X Induces Ferroptosis in KRAS-Driven Lung Canc

  2026-06-03

  This study demonstrates that DDX3X is essential for maintaining antioxidative homeostasis in KRAS-driven lung cancer, and its inhibition triggers ferroptosis via disruption of cysteine and glutathione metabolism. The findings suggest DDX3X as a promising therapeutic target, with important implications for overcoming drug resistance in lung cancer treatment.

• Bestatin-Related Aminopeptidase Inhibitor Phebestin Shows Po

  2026-06-03

  The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a potent agent against both chloroquine-sensitive and resistant Plasmodium falciparum strains. By targeting key parasite peptidases, phebestin demonstrates nanomolar efficacy, low cytotoxicity, and significant reduction of parasitemia in vivo, highlighting new directions for antimalarial drug development.

• NLRP10 Regulates Keratinocyte Survival and Skin Barrier in A

  2026-06-02

  This study establishes NLRP10 as a crucial regulator of epidermal homeostasis, showing how its downregulation in atopic dermatitis impairs keratinocyte survival and differentiation via p63 stabilization. The findings clarify the genetic and mechanistic links between NLRP10 and AD, highlighting new therapeutic targets for restoring skin barrier function.

• E-64: Advanced Mechanistic Insights for Precision Cysteine P

  2026-06-02

  Explore how E-64, a potent L-trans-epoxysuccinyl peptide, enables mechanistic dissection of cysteine protease function in cellular and viral models. This article provides in-depth analysis, unique protocol guidance, and critical reference integration for researchers seeking rigorous assay design.

• Y-27632 and the Future of Cytoskeletal Therapeutics in IBD

  2026-06-01

  This thought-leadership article explores how APExBIO’s Y-27632—a selective ROCK inhibitor—empowers translational researchers to strategically modulate cytoskeletal dynamics in models of mucosal inflammation and epithelial repair. Drawing on mechanistic insight, quantitative data, and recent discoveries in Treg-epithelial crosstalk, we provide experimental, competitive, and translational guidance for advancing disease modeling and regenerative strategies, with special attention to the evolving landscape of IBD research.

• ML-7 Hydrochloride: Benchmarking a Myosin Light Chain Kinase

  2026-06-01

  ML-7 hydrochloride is a potent, selective myosin light chain kinase inhibitor with a Ki of 300 nM, validated in cardiovascular and endothelial dysfunction models. It regulates myosin light chain phosphorylation and has demonstrated protective effects in ischemia/reperfusion injury research. This article compiles verifiable evidence, workflow best practices, and current limitations for ML-7 hydrochloride as a research tool.

• Resiniferatoxin (RTX): Precision TRPV1 Inactivation for Oste

  2026-05-31

  Explore how Resiniferatoxin (RTX) delivers ultra-potent, selective and long-lasting relief from osteoarthritis pain by targeting TRPV1 channels. This in-depth analysis reveals the latest clinical insights and protocol considerations for RTX research.

• Cy5 NHS ester(Et): Technical Use Guide for Protein Labeling

  2026-05-30

  Cy5 NHS ester(Et) is a water-soluble, amine-reactive fluorescent dye optimized for labeling primary amines in proteins and biomolecules. It is ideally used in workflows requiring immediate-use fluorescent probes for immunofluorescence, flow cytometry, and fluorescence microscopy. This product should not be used in ethanol-based protocols or for workflows that demand long-term storage of dye solutions.

• ERADECs: Small-Molecule Strategy for Degrading Transmembrane

  2026-05-29

  Song et al. (2026) introduce ERAD-engaging chimeras (ERADECs), a small-molecule technology that repurposes the ER-associated degradation pathway to selectively degrade transmembrane proteins. This approach achieves sub-nanomolar efficacy against targets like PD-L1 and offers new avenues for research on membrane protein modulation.

• Pomalidomide (CC-4047): Applied Workflows in Hematological R

  2026-05-29

  Pomalidomide (CC-4047) empowers hematological malignancy research by enabling precise immunomodulation and robust tumor microenvironment assays. This guide details advanced experimental workflows, protocol enhancements, and troubleshooting strategies that maximize reproducibility and insight across multiple myeloma and erythroid differentiation studies.

• Gastrin I Peptide in Human GI Models: Protocols & Innovation

  2026-05-28

  Harness the precision of human Gastrin I peptide for advanced gastric acid secretion pathway research with hiPSC-derived organoids. This guide delivers actionable protocols, troubleshooting insights, and benchmarks APExBIO's product for reproducibility and translational impact.

14755 records 1/984 page Next 12345 下5页 Last page